Role of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer

Table 1 General patient characteristics, n (%)

Characteristic	Conventional chemotherapy group, n = 62	HIPEC group, n = 51	P value
Sex			0.887
Male	43	36
Female	19	15
Age in yrmean ± SD	61.5 ± 8.6	60.9 ± 7.1	0.682
Operation method			0.767
Proximal gastrectomy	4 (6.45)	2 (3.92)
Distal gastrectomy	34 (54.84)	24 (47.06)
Total gastrectomy	24 (38.71)	25 (49.02)
Pathological T staging			0.502
T3	6 (9.68)	7 (13.72)
T4	56 (90.32)	44 (86.27)
Pathological N staging			0.656
N0	8 (12.90)	6 (11.76)
N1	21 (33.87)	17 (33.33)
N2	26 (41.94)	20 (39.22)
N3	7 (11.29)	8 (15.69)
Tumor perforation			0.276
Yes	23 (3.22)	1 (1.96)
No	57 (91.94)	43 (84.31)
Chemotherapy			0.458
XELOX	6 (9.68)	3 (5.89)
SOX	56 (90.32)	48 (94.12)
Hospital stay, mean ± SD	11.8 ± 2.8	13.4 ± 3.5	0.008

HIPEC: Hyperthermic intraperitoneal perfusion; XELOX: Capecitabine and oxaliplatin; SOX: Tegafur gimeracil and oxaliplatin.

Table 2 Complications, n (%)

Complication	Conventional chemotherapy group	HIPEC group	P value
Anastomotic fistula	0 (0.00)	0 (0.00)	-
Anastomotic bleeding	1 (1.61)	1 (1.96)	> 0.05
Abdominal hemorrhage	1 (1.61)	1 (1.96)	> 0.05
Abdominal abscess	2 (3.23)	1 (1.96)	> 0.05
Intestinal obstruction	3 (4.84)	4 (7.84)	> 0.05
Diarrhea	5 (8.06)	6 (11.76)	> 0.05
Cardiovascular abnormalities	5 (8.06)	7 (13.73)	> 0.05
Pulmonary infection	1 (1.61)	2 (3.92)	> 0.05
Urinary tract infection	2 (3.23)	3 (5.88)	> 0.05
Electrolyte disturbance	6 (9.68)	8 (15.69)	> 0.05
Myelosuppression	7 (11.29)	7 (13.73)	> 0.05
Clavien-Dindo classification
I	0	0	-
II	29 (46.8)	37 (72.5)	> 0.05
IIIa	3 (4.84)	2 (3.92)	> 0.05
IIIb	1 (1.61)	1 (1.96)	> 0.05
IVa	0	0	-
IVb	0	0	-
V	0	0	-

HIPEC: Hyperthermic intraperitoneal perfusion.